IN8bio, Inc. (INAB), a clinical-stage biopharmaceutical company, Friday announced promising results from its Phase 1 trials of INB-100, an allogeneic gamma-delta T cell therapy for high-risk acute myeloid leukemia or AML.
The data, presented at the 2025 Transplantation & Cellular Therapy or TCT Meetings, showed that INB-100 demonstrated impressive durability, with no AML relapses observed in any patients over a median follow-up of 20.1 months.
The 1-year progression-free survival or PFS rate stood at 90.9 percent, and the 1-year overall survival or OS rate was 100 percent, surpassing historical controls.
The therapy also displayed a favorable safety profile, with no cytokine release syndrome or CRS, neurotoxicity or ICANS, or dose-limiting toxicities or DLTs observed.
These results highlight INB-100's potential to provide long-term remissions in AML patients post-transplant.
Commenting on the findings, William Ho, CEO of IN8bio, said, "The durability of response and safety profile observed to date with INB-100 support its potential to set a new standard in post-transplant leukemia management."
IN8bio is accelerating patient enrollment for the INB-100 program and expects to complete enrollment of the expansion cohort by 2025.
Currently, INAB is trading at $0.31, down 3.23 percent on the Nasdaq..
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.